Parathyroid disorders in older adults represent a highly complex clinical issue because aging simultaneously modifies the biological background on which the calcium-parathyroid hormone (PTH)-vitamin D axis acts and the clinical context in which parathyroid disorders are recognized and treated. With advancing age, the prevalence of chronic kidney disease increases, vitamin D deficiency becomes more common, the use of medicines that interfere with serum calcium rises, skeletal fragility worsens and cardiovascular vulnerability becomes greater. In this setting, the same biochemical abnormality may have a different meaning from that observed in younger adults, and the boundary between a compensatory adaptation and clinically relevant disease becomes less distinct.
From a practical perspective, this field is dominated by three conditions: primary hyperparathyroidism, which is particularly common in older age groups; secondary hyperparathyroidism associated with chronic kidney disease (CKD), malabsorption or vitamin D deficiency; and acquired hypoparathyroidism, most commonly postsurgical, whose management in older adults requires a particularly careful balance between symptomatic stability and renal safety. Clinical presentation also tends to be less typical in older patients: neurocognitive symptoms, fatigue, postural instability, sarcopenia and frailty may overlap with disorders of mineral metabolism, making an integrated interpretation of medical history, physical examination and laboratory findings essential.
Primary hyperparathyroidism is one of the endocrine disorders most characteristic of older age, with a peak incidence among postmenopausal women and a frequent mild or minimally symptomatic presentation, incidentally detected through slight hypercalcemia on routine blood tests. In older adults, the pre-test probability of primary hyperparathyroidism is higher than that of many other causes of hypercalcemia, and this guides the initial approach: confirmation of the serum calcium abnormality, correction for albumin or measurement of ionized calcium, and assessment of PTH as the principal discriminator. However, older age also increases the probability of alternative diagnoses, particularly malignancy-related or medicine-induced hypercalcemia, and the diagnostic evaluation must therefore remain systematic.
At the same time, secondary hyperparathyroidism is very common in older adults because even moderate chronic kidney disease reduces calcitriol production and alters phosphate balance, stimulating a chronic parathyroid response. This is compounded by vitamin D deficiency, which is promoted by reduced sunlight exposure, reduced cutaneous synthesis, suboptimal nutrition and comorbidities. Consequently, an elevated PTH level in an older person does not automatically indicate primary hyperparathyroidism, and distinguishing primary from secondary disease is a crucial diagnostic step with radically different therapeutic implications.
Hypoparathyroidism is less common as a primary disorder in older adults, but it becomes clinically relevant because of the increasing number of neck procedures and a history of previous thyroidectomy or parathyroidectomy. Older adults are also more vulnerable to the complications of conventional replacement therapy with calcium and active vitamin D, particularly hypercalciuria, nephrocalcinosis and declining renal function, and therefore require therapeutic targets focused more on safety than on numerical normalization.
Parathyroid pathophysiology in older adults should be understood as a system in which the functional reserve of the three main target compartments, bone, kidney and intestine, is reduced or more variable. Bone in older adults is often characterized by loss of mass, microarchitectural deterioration and, in some settings, increased turnover, resulting in greater vulnerability to fractures even in response to relatively modest variations in PTH signaling. In primary hyperparathyroidism, chronic exposure to inappropriately elevated PTH promotes increased remodeling with loss of bone mineral density, particularly at cortical sites, and contributes to fracture risk and reduced muscle strength, which in older adults translate into falls and disability.
The kidney is the second major determinant. Glomerular filtration commonly declines with age, while comorbidities that alter tubular handling of calcium and phosphate become more frequent. In primary hyperparathyroidism, the combination of hypercalcemia and hypercalciuria promotes nephrolithiasis and nephrocalcinosis. Even when stone disease is not clinically apparent, chronic hypercalcemia may contribute to declining renal function in an organ that is already vulnerable. In secondary hyperparathyroidism, by contrast, the kidney itself drives the increase in PTH through reduced calcitriol production, phosphate retention and abnormalities of mineralized bone metabolism, creating a feedback cycle that may progressively worsen.
Vitamin D is also a central regulator. Deficiency of 25-hydroxyvitamin D increases PTH secretion as a compensatory response and may aggravate skeletal fragility. In older adults, however, correction of vitamin D deficiency must be integrated with the etiological diagnosis because replenishment is often appropriate in primary hyperparathyroidism but requires caution and monitoring of serum calcium, whereas it may be irrelevant or even misleading in non-PTH-mediated hypercalcemia. The key clinical consideration is that older adults display greater variability in physiological set points and target-organ responses, and laboratory findings must therefore be interpreted contextually rather than automatically.
In older adults, parathyroid disorders rarely present with the classic textbook picture. Primary hyperparathyroidism may manifest with nonspecific symptoms such as fatigue, reduced physical performance, mood disturbances, difficulty concentrating and worsening frailty. Although these findings are not pathognomonic, they are clinically relevant because they may improve after definitive treatment in selected subgroups and may contribute to shared decision-making, particularly when biochemical abnormalities are mild but functional impairment is substantial.
Skeletal involvement is often the most clinically important component: osteopenia or osteoporosis, fragility fractures, bone pain, loss of height and kyphosis may be the first indication of chronic PTH excess or of chronic kidney disease-mineral and bone disorder (CKD-MBD) with secondary hyperparathyroidism. In older adults, the coexistence of postmenopausal osteoporosis, sarcopenia and vitamin D deficiency makes it easy to attribute all abnormalities to aging, but some patients have a correctable endocrine component that alters their subsequent fracture-risk trajectory.
From a renal perspective, stone disease may be absent or clinically silent, particularly when the patient does not report renal colic or is taking analgesics for other reasons. In this setting, investigation for nephrolithiasis or nephrocalcinosis with appropriate imaging, when indicated, may change the therapeutic strategy because renal involvement is a strong marker of severity and an important indication for definitive treatment in primary hyperparathyroidism.
Hypoparathyroidism may be more clinically unstable in older adults: paresthesia, cramps, tremor, postural instability and confusion may be incorrectly attributed to neuropathy, medicines or cognitive decline. In the presence of hypocalcemia, the risk of QT prolongation and arrhythmias is particularly important in patients with cardiac disease or polypharmacy. In this context, stability of ionized calcium becomes a safety priority rather than an absolute numerical goal.
Clinical suspicion often begins with laboratory findings. Confirmed hypercalcemia, even if mild, particularly when persistent, always requires differentiation between PTH-mediated and non-PTH-mediated causes. In older adults, this distinction is particularly important because primary hyperparathyroidism is common but is not the only cause, and the presence of weight loss, anemia, diffuse bone pain or rapid clinical deterioration may suggest a different etiology. The key step is to measure PTH and interpret it appropriately: an elevated or inappropriately normal PTH level in the presence of hypercalcemia strongly suggests primary hyperparathyroidism or, less commonly, a medicine-related form such as lithium-associated hyperparathyroidism; a suppressed PTH level shifts the evaluation towards non-parathyroid causes.
Suspicion of secondary hyperparathyroidism is instead raised by an elevated PTH level in the presence of normal or low serum calcium, particularly when impaired renal function, hyperphosphatemia or vitamin D deficiency coexist. In older adults, an elevated PTH level should not be normalized as a simple effect of aging: the response may be physiologically appropriate, but it may also signal evolving CKD-MBD or an uncorrected mineral imbalance that increases the risk of fractures, vascular calcification and functional decline.
Hypoparathyroidism should be suspected promptly when hypocalcemia is associated with hyperphosphatemia and a low or inappropriately normal PTH level, particularly following thyroid, parathyroid or other neck surgery. In older adults, the threshold for investigation should be low because symptoms may be subtle while cardiac and neurological consequences may be more clinically significant.
Typical situations in which an older adult requires structured parathyroid evaluation
These situations do not establish the diagnosis, but they reduce the most common error in older adults: attributing a potentially correctable endocrine disorder to age and comorbidity, or starting empirical treatment without a complete assessment of calcium, phosphate, magnesium, vitamin D and renal function.
Diagnosis of parathyroid disorders in older adults is primarily biochemical. In the presence of hypercalcemia, confirmation requires repeat testing and assessment of albumin-corrected calcium or ionized calcium. The next step is measurement of PTH. If PTH is elevated or inappropriately normal, the probability of primary hyperparathyroidism is high, and the evaluation should include 25-hydroxyvitamin D, creatinine with estimated glomerular filtration rate, phosphate and assessment of urinary calcium excretion, because the differential diagnosis includes familial hypocalciuric hypercalcemia, in which urinary calcium excretion is typically low and the management strategy is radically different.
Assessment of target-organ damage is an integral part of determining functional disease severity. From a skeletal perspective, bone densitometry and investigation for vertebral fractures, including subclinical fractures, are particularly important in older adults because the presence of fractures alters both risk assessment and therapeutic indications. From a renal perspective, investigation for nephrolithiasis or nephrocalcinosis and measurement of renal function are essential because older adults are more vulnerable to renal decline and because renal impairment is one of the criteria supporting definitive treatment in primary hyperparathyroidism.
In secondary hyperparathyroidism, diagnosis requires demonstration of the underlying causal context: CKD with abnormalities of mineral metabolism, vitamin D deficiency, malabsorption or the use of medicines that affect calcium and vitamin D metabolism. In this setting, interpretation of PTH should not aim to normalize a single measurement, but rather to assess trends and their consistency with serum calcium and phosphate over time, in accordance with international CKD-MBD recommendations, because biological and treatment-related variability is high in older adults.
The role of parathyroid imaging is frequently misunderstood. Ultrasonography and scintigraphy, as well as other localization techniques, do not establish the diagnosis of primary hyperparathyroidism and should not precede biochemical confirmation. Their role is preoperative, helping to plan a targeted procedure once the decision to operate has already been made. In older adults, this approach reduces unnecessary investigations and focuses resources on the factors that genuinely alter management: confirmation of PTH-mediated disease, assessment of target-organ damage and evaluation of surgical risk and expected benefit.
A useful classification in older adults should be oriented towards mechanism and therapeutic decision-making. Primary hyperparathyroidism is characterized by hypercalcemia with elevated or non-suppressed PTH and results from autonomous secretion by one or more parathyroid glands. It is the form most characteristic of older age and often presents mildly, but it may still have a significant effect on bone, kidney and physical performance.
Secondary hyperparathyroidism is an adaptive response to relative hypocalcemia or to signals arising from vitamin D deficiency or CKD-MBD. In older adults, the most common causes are chronic kidney disease and vitamin D deficiency, which often coexist. Tertiary hyperparathyroidism represents progression towards autonomous secretion after chronic stimulation, typically in advanced CKD or following kidney transplantation, and may cause hypercalcemia with markedly elevated PTH, requiring specific management strategies.
Hypoparathyroidism in older adults is predominantly acquired and is often postsurgical. Its practical classification depends on stability over time and the risk of renal complications: transient postoperative forms tend to resolve, whereas persistent disease requires long-term management with safety-oriented targets and close monitoring of serum calcium, phosphate and urinary calcium.
In older patients with primary hyperparathyroidism, treatment is guided by the principle that parathyroidectomy is the only curative therapy, but the decision must integrate indications, expected benefit and operative risk in the context of frailty and comorbidity. The most recent international guidelines define surgical criteria based on biochemical severity, skeletal and renal involvement, age and patient preferences. In older adults, age alone is not a contraindication, but assessment must consider cardiopulmonary reserve, anesthetic risk and the expected functional benefit. It is clinically important that, in real-world practice, many older adults who meet surgical criteria do not undergo an operation, often because of barriers related to frailty and multimorbidity, even when the disease is potentially curable.
When surgery is indicated and feasible, its value in older adults extends beyond normalization of serum calcium and includes reduction of the risk of progressive target-organ damage and improvement of the functional trajectory in selected patients. Evidence suggests that apparently asymptomatic older adults may experience improvements in functional capacity, which is particularly relevant when symptoms are masked by frailty or attributed to age. Patient selection is the key operational issue: clinicians must identify those with the most favorable benefit-risk ratio and ensure that surgery is performed in experienced centers, because surgical quality is one of the main determinants of outcome.
When surgery is not indicated or is not feasible, medical treatment aims to control the two main domains: hypercalcemia and skeletal fragility. Calcimimetics such as cinacalcet can reduce serum calcium in many patients with primary hyperparathyroidism and represent an option for those who cannot undergo surgery or are awaiting an operation, with monitoring of tolerability and response. For skeletal disease, antiresorptive agents such as bisphosphonates or denosumab may be considered when bone fragility is the dominant concern, with attention to renal function, the risk of hypocalcemia and the need for integrated management of mineral metabolism. In older adults, the goal is often to reduce fracture risk rather than fully correct the PTH level, and this requires the calcium and skeletal components of treatment to be addressed separately and coherently.
Correction of vitamin D deficiency is frequently appropriate even in primary hyperparathyroidism, but in older adults it requires caution and monitoring of serum calcium because replenishment may alter urinary calcium excretion and affect mineral balance. Nutritional and behavioral measures include adequate hydration and review of medicines that increase serum calcium or complicate interpretation, such as thiazides and lithium, whenever clinically feasible.
In secondary hyperparathyroidism caused by CKD-MBD, the strategy is different and should follow international guideline principles: phosphate control, correction of vitamin D deficiency, and use of vitamin D analogues and calcimimetics in appropriate settings, while avoiding aggressive correction that increases the risk of hypercalcemia, hyperphosphatemia or vascular calcification. Therapeutic variability is considerable in older adults with CKD, and management must be individualized because the priority is to reduce clinically meaningful events, such as fractures and progression of vascular damage, rather than to pursue isolated numerical targets.
For hypoparathyroidism in older adults, conventional treatment with calcium and active vitamin D remains central, but it should be implemented using safety-oriented targets. It is often more appropriate to maintain serum calcium within the low-normal range or slightly below it, thereby reducing the risk of hypercalciuria and renal complications. In older adults, particular attention to diuretic use, renal function and hydration is required because small therapeutic errors may lead to major clinical events.
Follow-up should focus on the factors that alter prognosis. In primary hyperparathyroidism managed conservatively, monitoring includes serum calcium, renal function, vitamin D and periodic assessment of skeletal risk, with bone densitometry and investigation for vertebral fractures when clinically indicated. In older adults, monitoring frequency should be adapted to biochemical stability and overall risk: a frail patient with fluctuating serum calcium or receiving medical treatment requires more frequent assessment than a patient with stable disease.
In patients receiving calcimimetics, follow-up should verify stability of serum calcium and the absence of iatrogenic hypocalcemia, while also incorporating assessment of skeletal risk because correction of hypercalcemia does not provide equivalent skeletal protection. In patients treated with antiresorptive agents, monitoring should include renal function and, with denosumab, the risk of hypocalcemia, particularly when CKD coexists and vitamin D status is suboptimal.
In secondary hyperparathyroidism caused by CKD, surveillance should be integrated with nephrological management and should consider trends in PTH, calcium and phosphate, avoiding treatment changes in reaction to isolated blood test results. In older adults, adherence and gastrointestinal tolerability of phosphate binders may cause instability, and follow-up should include a realistic assessment of the prescribed treatment regimen.
In hypoparathyroidism, follow-up is primarily focused on safety: serum calcium, phosphate, urinary calcium when appropriate and renal function. Older adults are more susceptible to nephrocalcinosis and declining glomerular filtration rate, and treatment must therefore be continually adjusted to minimize exposure to hypercalciuria and hypercalcemia while maintaining adequate symptom control.
Prognosis depends on etiology and the quality of management. Many older adults with mild primary hyperparathyroidism may be followed conservatively when no severity criteria are present and reliable follow-up can be ensured. However, older adults have lower organ reserve, and the same chronic exposure to hypercalcemia and PTH may therefore have a greater effect on fracture risk, renal function and physical performance than in younger adults. Prognosis is consequently more dynamic and is linked to the progression of frailty and the occurrence of sentinel events such as fractures and renal decline.
When parathyroidectomy is feasible and indicated, prognosis may improve substantially because definitive treatment interrupts the underlying pathophysiological process. In older adults, benefit is often measured in terms of fracture prevention, renal stabilization and functional improvement rather than years of survival, and prognosis should therefore be discussed from the perspective of quality of life and preservation of independence.
In secondary hyperparathyroidism caused by CKD, prognosis is dominated by kidney disease and the cardiovascular and skeletal risks associated with CKD-MBD. Appropriate management of mineral metabolism may reduce complications, but the realistic objective in older adults is to limit progression and instability while avoiding therapies that promote hypercalcemia or calcification. In hypoparathyroidism, prognosis depends on maintaining a stable and safe balance, preventing iatrogenic renal complications and ensuring symptom control with a treatment burden compatible with adherence and frailty.